1-3 of 3
M Hirata
Close
Sort by
Journal Articles

Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study

Laurie H Sehn, MDMPH, Alex F. Herrera, MD, Matthew J Matasar, Manali Kamdar, Sarit Assouline, Mark Hertzberg, Tae Min Kim, Won-Seog Kim, Andrew McMillan, Muhit Özcan, Jamie M Hirata, Elicia Penuel, Ji Cheng, Grace Ku, Christopher R Flowers, MDMS
Journal: Blood
Blood (2018) 132 (Supplement 1): 1683.
https://doi.org/10.1182/blood-2018-99-118551
Published: 2018
Journal Articles

Addition of Polatuzumab Vedotin to Bendamustine and Rituximab (BR) Improves Outcomes in Transplant-Ineligible Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Versus BR Alone: Results from a Randomized Phase 2 Study

Laurie H. Sehn, MDMPH, Alex F. Herrera, MD, Matthew J. Matasar, MD, Manali Kamdar, Andrew K. McMillan, FRCP, Tae Min Kim, Won Seog Kim, MD, Ph. D., Mark Hertzberg, MBBS, PhD, Muhit Ozcan, MD, Elicia Penuel, Ji Cheng, Jamie M. Hirata, Grace Ku, Christopher Flowers, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2821.
https://doi.org/10.1182/blood.V130.Suppl_1.2821.2821
Published: 2017
Journal Articles

Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis

T Yamagami, H Sugiyama, K Inoue, H Ogawa, T Tatekawa, M Hirata, T Kudoh, T Akiyama, A Murakami, T Maekawa
Journal: Blood
Blood (1996) 87 (7): 2878–2884.
https://doi.org/10.1182/blood.V87.7.2878.bloodjournal8772878
Published: 1996